Cargando…

New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4

A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relev...

Descripción completa

Detalles Bibliográficos
Autores principales: Anobile, Dario P., Niso, Mauro, Puerta, Adrian, Fraga Rodrigues, Stephanie M., Abatematteo, Francesca S., Avan, Amir, Abate, Carmen, Riganti, Chiara, Giovannetti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911630/
https://www.ncbi.nlm.nih.gov/pubmed/35268783
http://dx.doi.org/10.3390/molecules27051682
_version_ 1784666866968428544
author Anobile, Dario P.
Niso, Mauro
Puerta, Adrian
Fraga Rodrigues, Stephanie M.
Abatematteo, Francesca S.
Avan, Amir
Abate, Carmen
Riganti, Chiara
Giovannetti, Elisa
author_facet Anobile, Dario P.
Niso, Mauro
Puerta, Adrian
Fraga Rodrigues, Stephanie M.
Abatematteo, Francesca S.
Avan, Amir
Abate, Carmen
Riganti, Chiara
Giovannetti, Elisa
author_sort Anobile, Dario P.
collection PubMed
description A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relevant antiproliferative activity with half maximal inhibitory concentration (IC50) values ranging from 0.701 to 0.825 μM. The cytotoxic activity was associated with induction of apoptosis, resulting in apoptotic indexes higher than those observed after exposure to a clinically relevant concentration of the gemcitabine, the first-line drug used against PDAC. Interestingly, FA4 was also able to significantly inhibit the migration rate of both PDAC-1 and PDAC-2 cells in the scratch wound-healing assay. In conclusion, our results support further studies to improve the library of thiosemicarbazones targeting the σ-2 receptor for a deeper understanding of the relationship between the biological activity of these compounds and the development of more efficient anticancer compounds against PDAC.
format Online
Article
Text
id pubmed-8911630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89116302022-03-11 New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 Anobile, Dario P. Niso, Mauro Puerta, Adrian Fraga Rodrigues, Stephanie M. Abatematteo, Francesca S. Avan, Amir Abate, Carmen Riganti, Chiara Giovannetti, Elisa Molecules Article A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relevant antiproliferative activity with half maximal inhibitory concentration (IC50) values ranging from 0.701 to 0.825 μM. The cytotoxic activity was associated with induction of apoptosis, resulting in apoptotic indexes higher than those observed after exposure to a clinically relevant concentration of the gemcitabine, the first-line drug used against PDAC. Interestingly, FA4 was also able to significantly inhibit the migration rate of both PDAC-1 and PDAC-2 cells in the scratch wound-healing assay. In conclusion, our results support further studies to improve the library of thiosemicarbazones targeting the σ-2 receptor for a deeper understanding of the relationship between the biological activity of these compounds and the development of more efficient anticancer compounds against PDAC. MDPI 2022-03-04 /pmc/articles/PMC8911630/ /pubmed/35268783 http://dx.doi.org/10.3390/molecules27051682 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anobile, Dario P.
Niso, Mauro
Puerta, Adrian
Fraga Rodrigues, Stephanie M.
Abatematteo, Francesca S.
Avan, Amir
Abate, Carmen
Riganti, Chiara
Giovannetti, Elisa
New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
title New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
title_full New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
title_fullStr New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
title_full_unstemmed New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
title_short New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
title_sort new pharmacological strategies against pancreatic adenocarcinoma: the multifunctional thiosemicarbazone fa4
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911630/
https://www.ncbi.nlm.nih.gov/pubmed/35268783
http://dx.doi.org/10.3390/molecules27051682
work_keys_str_mv AT anobiledariop newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT nisomauro newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT puertaadrian newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT fragarodriguesstephaniem newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT abatematteofrancescas newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT avanamir newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT abatecarmen newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT rigantichiara newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4
AT giovannettielisa newpharmacologicalstrategiesagainstpancreaticadenocarcinomathemultifunctionalthiosemicarbazonefa4